Bronchodilators in COPD: Impact of β-agonists and anticholinergics on severe exacerbations and mortality

References

• AaronSDVandemheenKLHebertP2003Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary diseaseN Engl J Med34826182512826636
   PubMed Web of Science ®Google Scholar
• AlsaeediASinDDMcAlisterFA2002The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trialsAm J Med113596512106623
   PubMed Web of Science ®Google Scholar
• AnthonisenNRConnettJEEnrightPL2002Hospitalizations and mortality in the Lung Health StudyAm J Crit Care Med1663339
   Web of Science ®Google Scholar
• AshutoshKLangH1984Comparison between long-term treatment of chronic bronchitic airway obstruction with ipratropium bromide and metaproterenolAnn Allergy5340166238558
   PubMedGoogle Scholar
• [ATP] American Thoracic Society1995Standards for the diagnosis and care of patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med152(5 Pt 2)S771217582322
   PubMed Web of Science ®Google Scholar
• BarnesPJ2004The role of anticholinergics in chronic obstructive pulmonary diseaseAm J Med117Suppl 12A24S32S15693640
   PubMed Web of Science ®Google Scholar
• BarrRGBourbeauJCamargoCA2005Inhaled tiotropium for stable chronic obstructive pulmonary diseaseCochrane Database Syst Rev2CD00287615846642
   PubMedGoogle Scholar
• BoydGMoriceAHPounsfordJC1997An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD)Eur Respir J10815219150318
   PubMed Web of Science ®Google Scholar
• BrusascoBHodderRMiravitllesM2003Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPDThorax5839940412728159
   PubMed Web of Science ®Google Scholar
• BrusascoVHodderRMiravitllesM2006Letter to the editor. Health outcomes following treatment for 6 months with once daily tiotropium compared with twice daily salmeterol in patients with COPDThorax619116396956
   PubMed Web of Science ®Google Scholar
• CalverleyPMBoonsawatWCsekeZ2003Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary diseaseEur Respir J229121914680078
   PubMed Web of Science ®Google Scholar
• CasaburiRBriggsDDJrDonohueJF2000The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multi-center trial. The US Tiotropium Study GroupChest118129430211083677
   PubMed Web of Science ®Google Scholar
• CasaburiRMahlerDAJonesPW2002A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary diseaseEur Respir J192172411866001
   PubMed Web of Science ®Google Scholar
• CelliBRMacNeeW2004Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paperEur Respir J239324615219010
   PubMed Web of Science ®Google Scholar
• Combivent Inhalation Solution Study Group1997Routine nebulized ipratropium and albuterol are better than either alone in COPD. The Combivent Inhalation Solution Study GroupChest1121514219404747
   PubMed Web of Science ®Google Scholar
• CookDGuyattGWongE2001Regular versus as-needed short-acting inhaled beta-agonist therapy for chronic obstructive pulmonary diseaseAm J Respir Crit Care Med163859011208630
   PubMed Web of Science ®Google Scholar
• DonohueJFMenjogeSKestenS2003Tolerance to bronchodilating effects of salmeterol in COPDRespir Med9710142014509555
   PubMed Web of Science ®Google Scholar
• FahyJVBousheyHA1995Controversies involving inhaled beta-agonists and inhaled corticosteroids in the treatment of asthmaClin Chest Med16715338565410
   PubMed Web of Science ®Google Scholar
• [FDA] US Food and Drug Administration Advisory Committee2005Serevent, Advair, Foradil withdrawals to be considered by Advisory Committee [online]882005 URL: http://www.fdaadvisory-committee.com/FDC/AdvisoryCommittee/Committees/Pulmonary-Allergy%20Drugs/071305_betasafety/071305_BroncoP.htm
   Google Scholar
• [FDA] US Food and Drug Administration2002NDA 21–395 Spiriva (Tiotropium bromide) inhalation powder for COPD [online] Accessed on 10 August 2005. URL: http://www.fda.gov/OHRMS/DOCKETS/ac/02/briefing/3890B1_05_Clinical%20Briefing.doc
   Google Scholar
• FriedmanMSerbyCWMenjogeSS1999Pharmocoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPDChest1156354110084468
   PubMed Web of Science ®Google Scholar
• GanWQManSFSinDD2005Effects of inhaled corticosteroids on sputum cell counts in stable chronic obstructive pulmonary disease: a systematic review and a meta-analysisBMC Pulm Med5315707484
   PubMedGoogle Scholar
• GlaxoSmithKline2006GSK announces positive results of Seretide study in patients with chronic obstructive pulmonary disease (COPD) [online] Accessed on 18 August 2006. URL: http://www.gsk.com/ControllerServlet?appld=4&pageld=402&newsid=780
   Google Scholar
• KarpelJP1991Bronchodilator responses to anticholinergic and beta-adrenergic agents in acute and stable COPDChest9987161672634
   PubMed Web of Science ®Google Scholar
• LipworthBJ1992Risks versus benefits of inhaled beta 2-agonists in the management of asthmaDrug Saf754701346963
   PubMed Web of Science ®Google Scholar
• MahlerDAWirePHorstmanD2002Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary diseaseAm J Respir Crit Care Med16610849112379552
   PubMed Web of Science ®Google Scholar
• McCroryDCBrownCDGelfandSE2001Management of acute exacerbations of COPD. A summary and appraisal of published evidenceChest119119020911296189
   PubMed Web of Science ®Google Scholar
• McCroryDCBrownCD2001Inhaled short-acting beta2-agonists versus ipratropium for acute exacerbations of chronic obstructive pulmonary diseaseCochrane Database Syst Rev2CD00298411406052
   PubMedGoogle Scholar
• MichaudCMMurrayCJBloomBR2001Burden of disease—implications for future researchJAMA285535911176854
   PubMed Web of Science ®Google Scholar
• NanniniLCatesCJLassersonTJ2004Combined corticosteroid and long acting beta-agonist in one inhaler for chronic obstructive pulmonary diseaseCochrane Database Syst Rev3CD00379415266502
   PubMedGoogle Scholar
• [NCCCC] National Collaborating Centre for Chronic Conditions2004Chronic obstructive pulmonary disease. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary careThorax59Suppl 11232
   Google Scholar
• NelsonHSWeissSTBleeckerER2006The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterolChest129152616424409
   PubMed Web of Science ®Google Scholar
• NiewoehnerDE2002The role of systemic corticosteroids in acute exacerbation of chronic obstructive pulmonary diseaseAm J Respir Med1243814720044
   PubMedGoogle Scholar
• NiewoehnerDERiceKCoteC2005Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily, inhaled anticholinergic bronchodilator: a randomized trialAnn Intem Med14331726
   PubMed Web of Science ®Google Scholar
• OostenbrinkJBRutten-van MolkenMPAlMJ2004One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary diseaseEur Respir J23241914979498
   PubMed Web of Science ®Google Scholar
• PauwelsRABuistASCalverleyPM2001Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summaryAm J Respir Crit Care Med16312567611316667
   PubMedGoogle Scholar
• RamseySD2000Suboptimal medical therapy in COPD: exploring the causes and consequencesChest1172 Suppl33S7S10673472
   PubMed Web of Science ®Google Scholar
• RennardSISerbyCWGhafouriM1996Extended therapy with ipratropium is associated with improved lung function in patients with COPD. A retrospective analysis of data from seven clinical trialsChest11062708681667
   PubMed Web of Science ®Google Scholar
• RennardSIAndersonWZuwallackR2001Use of a long-acting inhaled beta 2-adrenegic agonist, salmeterol xinafoate, in Patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med16310879211316640
   PubMed Web of Science ®Google Scholar
• RocheNLepageTBourcereauJ2001Guidelines versus clinical practice in the treatment of chronic obstructive pulmonary diseaseEur Respir J18903811829094
   PubMed Web of Science ®Google Scholar
• RossiAKristufekPLevineBE2002Comparison of the efficacy, tolerability, and safety of formoterol dry posder and oral, slow-release theophylline in the treatment of COPDChest12110586911948033
   PubMed Web of Science ®Google Scholar
• RudolfM2000The reality of drug use in COPD: the European perspectiveChest1172 Suppl29S32S10673471
   PubMed Web of Science ®Google Scholar
• SalpeterSRBuckleyNSOrmistonTM2006Long-acting beta-agonists increase severe asthma exacerbations and asthma-related deaths: meta-analysis of randomized controlled trialsAnn Intern Med1449041216754916
   PubMed Web of Science ®Google Scholar
• SalpeterSRBuckleyNSSalpeterEE2006Meta-analysis: Anticholinergics, but not beta-agonists, reduce severe exacerbations and respiratory mortality in COPDJ Gen Intern Med2110111916970553
   PubMed Web of Science ®Google Scholar
• SalpeterSRBuckleyNS2006Systematic review of clinical outcomes in chronic obstructive pulmonary disease: β-Agonist use compared with anticholinergics and inhaled corticosteroidsClin Rev Allergy Immunol312193017085795
   PubMed Web of Science ®Google Scholar
• SalpeterSROrmistonTMSalpeterEE2004Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysisChest12523092115189956
   PubMed Web of Science ®Google Scholar
• SalpeterSROrmistonTMSalpeterEE2004Meta-analysis: respiratory tolerance to regular beta2-agonist use in patients with asthmaAnn Intern Med1408021315148067
   PubMed Web of Science ®Google Scholar
• SearsMRTaylorDRPrintCG1990Regular inhaled beta-agonist treatment in bronchial asthmaLancet336139161978871
   PubMed Web of Science ®Google Scholar
• SestiniPRenzoniERobinsonS2002Short-acting beta 2 agonists for stable chronic obstructive pulmonary diseaseCochrane Database Syst Rev4CD00149512519559
   PubMedGoogle Scholar
• SinDDLacyPYorkE2004Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med170760515229100
   PubMed Web of Science ®Google Scholar
• SinDDMcAlisterFAManSF2003Contemporary management of chronic obstructive pulmonary disease: scientific reviewJAMA29023011214600189
   PubMed Web of Science ®Google Scholar
• SinDDWuLAndersonJA2005Inhaled corticosteroids and mortality in chronic obstructive pulmonary diseaseThorax60992716227327
   PubMed Web of Science ®Google Scholar
• SinghJMPaldaVAStanbrookMB2002Corticosteroid therapy for patients with acute exacerbations of chronic obstructive pulmonary disease: a systematic reviewArch Intern Med16225273612456224
   PubMed Web of Science ®Google Scholar
• SullivanSDRamseySDLeeTA2000The economic burden of COPDChest1172 Suppl5S9S10673466
   PubMed Web of Science ®Google Scholar
• SutherlandERAllmersHAyasNT2003Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysisThorax589374114586043
   PubMed Web of Science ®Google Scholar
• SzafranskiWCukierARamirezA2003Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary diseaseEur Respir J21748112570112
   PubMed Web of Science ®Google Scholar
• TashkinDPAshutoshKBleeckerER1986Comparison of the anticholinergic bronchodilator ipratropium bromide with metaproterenol in chronic obstructive pulmonary disease. A 90-day multi-center studyAm J Med815A81902947465
   PubMed Web of Science ®Google Scholar
• TashkinDPCooperCB2004The role of long-acting bronchodilators in the management of stable COPDChest1252495914718448
   PubMed Web of Science ®Google Scholar
• TaylorDRSearsMCockcroftDW1996The beta-agonist controversyMed Clin N Am80719488676612
   PubMed Web of Science ®Google Scholar
• TaylorJKotchARiceK2001Ipratropium bromide hydrofluoro-alkane inhalation aerosol is safe and effective in patients with COPDChest12012536111591569
   PubMed Web of Science ®Google Scholar
• van GrunsvenPMvan SchayckCPDerenneJP1999Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysisThorax5471410343624
   PubMed Web of Science ®Google Scholar
• Van OverveldFJDemkowUGoreckaD2006Differences in responses upon corticosteroid therapy between smoking and non-smoking patients with COPDJ Physiol Pharmacol57Suppl 42738217072055
   PubMed Web of Science ®Google Scholar
• van SchayckCPGraafsmaSJVischMB1990Increased bronchial hyperresponsiveness after inhaling salbutamol during 1 year is not caused by subsensitization to salbutamolJ Allergy Clin Immunol867938001977787
   PubMed Web of Science ®Google Scholar
• WadboMLofdahlCGLarssonK2002Effects of formoterol and ipratropium bromide in COPD: a 3-month placebo-controlled studyEur Respir J2011384612449166
   PubMed Web of Science ®Google Scholar
• Wood-BakerRWaltersEHGibsonP2001Oral corticosteroids for acute exacerbations of chronic obstructive pulmonary diseaseCochrane Database Syst Rev2CD00128811405984
   PubMedGoogle Scholar